查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715330

心臟生物標記市場（按生物標記類型、臨床環境、應用和最終用戶分類）—2025-2030 年全球預測

Cardiac Biomarker Market by Biomarker Type, Clinical Setting, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2024 年心臟生物標記市場規模將達到 132.6 億美元，到 2025 年將達到 144.1 億美元，到 2030 年將達到 223.7 億美元，複合年成長率為 9.10%。

主要市場統計數據
基準年2024年 132.6億美元
預計年份：2025年 144.1億美元
預測年份 2030 223.7億美元
複合年成長率（%） 9.10%

在當今快速變化的醫療保健環境中，心臟生物標記已成為現代診斷的重要組成部分。心臟生物標記已成為評估心臟相關併發症的重要指標，可以引導醫療專業人員做出快速且準確的診斷。本報告透過全面審視當前市場格局奠定了基礎，其中不斷發展的診斷需求與最新的技術進步相遇。

心臟生物標記研究不僅僅是數字和數據；它匯集了正在進行的創新，這些創新正在改變患者照護並影響臨床醫生如何做出關鍵決策。對準確、快速診斷工具的需求不斷成長，導致了對研發的大量投資。相關人員現在可以深入了解臨床趨勢、預測能力和市場動態。

深入研究這項分析可以揭示生物標記研究背後的層次，從突破性的臨床研究到現實世界的應用。不可否認，我們迫切需要適應新的市場動態並利用創新解決方案來改善患者的治療效果。透過強調心臟診斷的多方面方面，本概述為決策者提供了關鍵見解，幫助他們增強策略並應對當今醫療保健的複雜挑戰。

改變心臟生物標記市場

近年來，心臟生物標記市場發生了變革性變化，凸顯了適應性策略對產業相關人員的重要性。先進數位技術的整合和測試流程的自動化不僅提高了準確性，而且顯著縮短了診斷時間。這種變化主要是由於重症加護環境中對快速診斷解決方案的需求日益成長。

檢測設計的創新和就地檢驗的出現擴大了即時、現場臨床評估的範圍。一個顯著的趨勢是朝著高度敏感和特異性的測試方向發展，這些測試現在在各種臨床環境中更容易實施。這些動態轉變正在重塑競爭格局，為滿足患者細微需求的創造性產品和策略鋪路。

投資者和決策者越來越意識到，為了保持競爭力，他們必須擁抱技術進步，最佳化業務效率，並整合針對患者特定情況的新型診斷方法。市場正在發生變化，不僅體現在所採用的技術上，還體現在不斷發展變化的監管和報銷環境上，這些環境要求更高的標準。因此，各公司正在重新調整其研究組合和產品平臺，以滿足對心臟健康監測的更高性能、可靠性和臨床效用的需求。

推動市場成長的關鍵細分洞察

心臟生物標記市場已被全面細分，以揭示這一專業領域的複雜性。考慮到生物標記類型，經過徹底的分析發現，BNP 和 NT-proBNP、肌酸激酶 (CK) MB、肌紅蛋白和肌鈣蛋白等指標正在廣泛的應用。每種生物標記都有其自身的臨床意義，有助於更全面地了解心臟健康。

此外，市場按臨床環境細分，實驗室檢測因就地檢驗的興起而得到補充。這種演變凸顯了使診斷工具適應不同臨床環境的必要性，確保集中實驗室和分散護理中心在測試準確性和速度方面保持共生關係。

此外，應用部分還提供了對診斷、預後和風險評估的關鍵作用的深入了解。具體來說，診斷過程經過細化，分為以急性冠狀動脈症候群、鬱血性和心肌梗塞為重點的子類別。透過這種細分，可以將每張臨床影像與一組適當的生物標記物相匹配。

最後，按最終用戶進行細分揭示了參與採用這些診斷工具的利害關係人的多樣性。從診斷實驗室和醫院診所到專門的研究實驗室，病人歷程反映了旨在改善患者預後的廣泛策略。每個細分層都有助於以有針對性的方式進行市場分析，從而根據精確的臨床需求實現客製化創新。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球心血管疾病的發生率正在上升
      • 心臟生物標記在醫學診斷的應用日益廣泛
      • 患者和醫療保健專業人員對早期診斷的認知日益增強
    • 限制因素
      • 與心臟生物標記相關的嚴格監管合規性
    • 機會
      • 與穿戴式科技公司合作進行即時心臟生物標記監測
      • 致力於推進心臟生物標記技術的研究舉措和資金激增
    • 任務
      • 將心臟生物標記與傳統診斷工具結合的複雜性
  • 市場區隔分析
    • 生物標記類型：肌鈣蛋白因其卓越的特異性和敏感性而變得重要
    • 應用：擴大心臟生物標記在風險評估的應用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

6. 心臟生物標記市場（依生物標記類型）

  • 介紹
  • BNP 和 NT-proBNP
  • 肌酸激酶（CK）MB
  • 肌紅蛋白
  • 肌鈣蛋白

7. 心臟生物標記市場（依臨床狀況）

  • 介紹
  • 實驗室測試
  • 就地檢驗

8. 心臟生物標記市場（按應用）

  • 介紹
  • 診斷
    • 急性冠狀動脈症候群
    • 鬱血性心臟衰竭衰竭
    • 心肌梗塞
  • 預後
  • 風險評估

第9章心臟生物標記市場（按最終用戶）

  • 介紹
  • 診斷實驗室
  • 醫院和診所
  • 研究所

10.美洲心臟生物標記市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

11.亞太心臟生物標記市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12. 歐洲、中東和非洲心臟生物標記市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories
  • Abcam plc
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • Epitope Diagnostics Inc.
  • F. Hoffmann-La Roche AG
  • Fujirebio Diagnostics Inc.
  • Guangzhou Wondfo BIoTech Co., Ltd.
  • Hologic Inc.
  • Johnson & Johnson Services, Inc.
  • Life Diagnostics, Inc.
  • LSI Medience Corporation
  • Meridian Bioscience, Inc.
  • Myriad RBM Inc.
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Quidel Corporation
  • QuidelOrtho Corporation
  • Randox Laboratories Limited
  • Sekisui Medical Co., Ltd.
  • Siemens Healthineers AG
  • Singulex, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
  • Trinity BIoTech plc
Product Code: MRR-433AB1DC288D

The Cardiac Biomarker Market was valued at USD 13.26 billion in 2024 and is projected to grow to USD 14.41 billion in 2025, with a CAGR of 9.10%, reaching USD 22.37 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 13.26 billion
Estimated Year [2025] USD 14.41 billion
Forecast Year [2030] USD 22.37 billion
CAGR (%) 9.10%

In today's fast-paced healthcare environment, the field of cardiac biomarkers has emerged as a pivotal element in modern diagnostics. Cardiac biomarkers serve as essential indicators in assessing heart-related complications, guiding medical professionals towards swift and accurate diagnoses. This report sets the stage by offering a comprehensive look at the current state of the market, where evolving diagnostic needs meet the latest technological advancements.

Research in cardiac biomarkers is not just about numbers and data; it encapsulates the ongoing innovations that are transforming patient care and influencing how clinicians make critical decisions. The growing demand for precise and rapid diagnostic tools has led to significant investments in research and development. Stakeholders are now equipped with insights that offer a detailed understanding of clinical trends, prognostic capabilities, and market dynamics.

As we delve deeper into this analysis, the layers behind biomarker research-from groundbreaking clinical studies to real-world application-become apparent. There is an undeniable urgency to adapt to emerging market dynamics and to harness innovative solutions that improve patient outcomes. By focusing on the multifaceted aspects of cardiac diagnostics, this summary provides decision-makers with key insights that enhance strategic planning and help navigate the complexities of today's healthcare challenges.

Transformative Shifts in the Cardiac Biomarker Landscape

Recent years have seen transformative shifts within the cardiac biomarker market that underscore the importance of adaptive strategies for industry stakeholders. The integration of advanced digital technologies and automation in laboratory testing processes has not only improved accuracy but also reduced the time-to-diagnosis significantly. These changes have been largely driven by the increased need for rapid diagnostic solutions in critical care settings.

Innovation in assay design and the emergence of point-of-care testing have broadened the scope for immediate and on-site clinical assessments. A noticeable trend is the move towards highly sensitive and specific tests, which are now more readily deployed in diverse clinical settings. Such dynamic transformations are reshaping the competitive landscape by paving the way for disruptive products and strategies that cater to nuanced patient needs.

Investors and decision-makers are increasingly recognising that maintaining a competitive edge requires embracing technological advancements, optimizing operational efficiencies, and integrating novel diagnostic approaches tailored to patient-specific profiles. The market shift is not only evident in the technology adopted but also in the evolving regulatory and reimbursement landscapes that demand higher standards. As a result, companies are realigning their research portfolios and product pipelines to better answer the call for enhanced performance, reliability, and clinical utility in monitoring cardiac health.

Key Segmentation Insights Driving Market Growth

The cardiac biomarker market is comprehensively segmented to illuminate the intricacies of this specialized field. When examined from the perspective of biomarker type, thorough analysis reveals that utilization spans across indicators such as BNP & NT-proBNP, Creatine Kinase (CK) MB, Myoglobin, and Troponins. Each biomarker carries its unique clinical significance and contributes to a layered understanding of cardiac health.

In addition, the market is dissected by clinical setting, where laboratory testing is complemented by the rise of point-of-care testing. This evolution underscores the necessity of aligning diagnostic tools with varied clinical environments, ensuring that both centralized labs and decentralized care centers maintain a symbiotic relationship in testing accuracy and speed.

Furthermore, the application segment provides insight into the pivotal roles of diagnosis, prognosis, and risk assessment. In particular, diagnostic processes are refined through sub-categories that focus on Acute Coronary Syndrome, Congestive Heart Failure, and Myocardial Infarction. Such granularity ensures that each clinical presentation is addressed with an appropriate suite of biomarkers.

Lastly, the segmentation based on end user reveals the diverse stakeholders involved in deploying these diagnostic tools. From diagnostic laboratories and hospitals & clinics to specialized research institutes, the adoption journey of cardiac biomarkers is reflective of a broad-based strategy aimed at enhancing patient outcomes. Each segmentation layer collectively contributes to a targeted approach in market analysis and encourages tailored innovations based on precise clinical demands.

Based on Biomarker Type, market is studied across BNP & NT-proBNP, Creatine Kinase (CK) MB, Myoglobin, and Troponins.

Based on Clinical Setting, market is studied across Laboratory Testing and Point Of Care Testing.

Based on Application, market is studied across Diagnosis, Prognosis, and Risk Assessment. The Diagnosis is further studied across Acute Coronary Syndrome, Congestive Heart Failure, and Myocardial Infarction.

Based on End User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Institutes.

Key Regional Insights Across Global Markets

The regional analysis of the cardiac biomarker market reveals distinct trends and growth trajectories that are shaped by localized economic, regulatory, and healthcare conditions. Within the Americas, robust healthcare infrastructures and high investment in medical research have fostered an environment ripe for innovations in diagnostic technologies. This region continues to serve as a leader in technology adoption and rapid commercialization of new diagnostic assays.

In contrast, the dynamics across Europe, Middle East & Africa are marked by an increasing emphasis on preventive care and the adoption of harmonized regulatory frameworks. Here, strategic collaborations among industry players have accelerated improvements in both technology and patient access to advanced diagnostic services.

The Asia-Pacific region has emerged as a powerhouse fueled by the rapid growth in healthcare infrastructure investments and a burgeoning middle class. Increased awareness and evolving lifestyle trends have spurred demand for early detection and risk stratification solutions, making this region a focal point for market expansion.

These regional insights are critical for understanding how macroeconomic factors and localized health policies drive the adoption of cardiac biomarker technologies. The interplay between regional market maturity and regulatory frameworks creates opportunities for both global and local players to refine their strategies and drive long-term sustainable growth.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Shaping the Cardiac Biomarker Market

At the forefront of innovation and market leadership, several key companies are driving the evolution of cardiac biomarkers through robust R&D, strategic alliances, and continuous product innovation. Industry leaders such as Abbott Laboratories, Abcam plc, and Becton, Dickinson and Company stand out as pioneers by setting high standards in assay development and clinical validation.

Other influential entities including Bio-Rad Laboratories Inc., bioMerieux SA, and Danaher Corporation have strategically invested in technologies that enhance sensitivity and specificity in biomarker detection. Firms like DiaSorin S.p.A. and Epitope Diagnostics Inc. are recognized for their cutting-edge research and commitment to quality, which collectively contribute to a more comprehensive understanding of cardiac pathophysiology.

The contributions from global giants such as F. Hoffmann-La Roche AG and Hologic Inc. reflect a broader trend of leveraging integrated diagnostic platforms to address diverse clinical needs. Not to be overlooked, companies like Johnson & Johnson Services, Inc., Life Diagnostics, Inc., and LSI Medience Corporation continue to make significant strides in advancing diagnostic accuracy.

Additionally, specialized firms including Meridian Bioscience, Inc., Myriad RBM Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Quidel Corporation and QuidelOrtho Corporation are instrumental in driving market segmentation and precision medicine initiatives. Moreover, Randox Laboratories Limited, Sekisui Medical Co., Ltd., Siemens Healthineers AG, Singulex, Inc., Sysmex Corporation, Thermo Fisher Scientific Inc., Tosoh Corporation, and Trinity Biotech plc further showcase the diverse and internationally interconnected nature of the cardiac biomarker market. Their collective innovations and market strategies underscore the importance of collaboration and dedicated research efforts in advancing cardiovascular diagnostics.

The report delves into recent significant developments in the Cardiac Biomarker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam plc, Becton, Dickinson and Company, Bio-Rad Laboratories Inc., bioMerieux SA, Danaher Corporation, DiaSorin S.p.A., Epitope Diagnostics Inc., F. Hoffmann-La Roche AG, Fujirebio Diagnostics Inc., Guangzhou Wondfo Biotech Co., Ltd., Hologic Inc., Johnson & Johnson Services, Inc., Life Diagnostics, Inc., LSI Medience Corporation, Meridian Bioscience, Inc., Myriad RBM Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Quidel Corporation, QuidelOrtho Corporation, Randox Laboratories Limited, Sekisui Medical Co., Ltd., Siemens Healthineers AG, Singulex, Inc., Sysmex Corporation, Thermo Fisher Scientific Inc., Tosoh Corporation, and Trinity Biotech plc. Actionable Recommendations for Leaders in Cardiac Biomarker Innovation

To navigate the rapidly evolving cardiac biomarker market, industry leaders must consider a multifaceted strategy that balances innovation with operational excellence. It is essential to invest in next-generation diagnostic technologies while maintaining rigorous validation protocols that meet international standards. In today's market, leveraging robust data analytics frameworks can help refine patient stratification and optimize clinical outcomes.

Companies should prioritize strategic partnerships that expand market reach and foster collaborative research initiatives. Enhancing communication channels with regulatory bodies will prove invaluable in navigating compliance landscapes. Moreover, a proactive approach to marketplace trends-particularly in emerging regions-will enable stakeholders to capitalize on new growth opportunities.

Another critical recommendation is to diversify product portfolios to address the dynamic needs of various end users, be they diagnostic laboratories, hospitals, or research institutes. Implementing agile R&D processes that swiftly adapt to breakthrough scientific insights will further solidify market positioning. By aligning internal capabilities with the shifting demands of the healthcare ecosystem, leaders can ensure that their organizations not only keep pace with industry changes but also pioneer innovations that transform patient care.

Conclusion of the Cardiac Biomarker Market Analysis

In summary, the cardiac biomarker market stands at a critical juncture where technological innovation meets evolving clinical demands. Through a detailed exploration of segmentation, regional dynamics, and competitive landscapes, it is evident that investment in diagnostic precision and strategic partnerships are key to sustained success.

The insights presented in this analysis emphasize a drive towards personalized healthcare and underscore the need for robust, innovative solutions that address acute cardiovascular conditions. Market leaders have a unique opportunity to redefine patient care and create lasting impact by integrating advanced biomarkers with traditional diagnostic strategies.

Ultimately, this comprehensive overview serves to illuminate the path forward in a market characterized by rapid growth, dynamic change, and immense potential for improved clinical outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of cardiovascular diseases globally
      • 5.1.1.2. Increasing adoption of cardiac biomarkers in medical diagnostics
      • 5.1.1.3. Rising awareness about early diagnosis among patients and healthcare providers
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory compliances associated with cardiac biomarkers
    • 5.1.3. Opportunities
      • 5.1.3.1. Partnerships with wearable tech companies for real-time cardiac biomarker monitoring
      • 5.1.3.2. Surge in research initiatives and funding focused on advancing cardiac biomarker technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of integrating cardiac biomarkers with traditional diagnostic tools
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Biomarker Type: Rising significance of troponins owing to their superior specificity and sensitivity
    • 5.2.2. Application: Expanding adoption of cardiac biomarkers for risk assessment
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cardiac Biomarker Market, by Biomarker Type

  • 6.1. Introduction
  • 6.2. BNP & NT-proBNP
  • 6.3. Creatine Kinase (CK) MB
  • 6.4. Myoglobin
  • 6.5. Troponins

7. Cardiac Biomarker Market, by Clinical Setting

  • 7.1. Introduction
  • 7.2. Laboratory Testing
  • 7.3. Point Of Care Testing

8. Cardiac Biomarker Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnosis
    • 8.2.1. Acute Coronary Syndrome
    • 8.2.2. Congestive Heart Failure
    • 8.2.3. Myocardial Infarction
  • 8.3. Prognosis
  • 8.4. Risk Assessment

9. Cardiac Biomarker Market, by End User

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Research Institutes

10. Americas Cardiac Biomarker Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cardiac Biomarker Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cardiac Biomarker Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. MediBuddy collaborates with Philips to introduce advanced Heart Health monitoring
    • 13.3.2. FDA accepts Cytokinetics' aficamten NDA, advancing innovative cardiac biomarker in HCM treatment
    • 13.3.3. Siemens Healthineers enhances heart failure diagnostics with the addition of NT-proBNPII assay to Atellica platform
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Abcam plc
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories Inc.
  • 5. bioMerieux SA
  • 6. Danaher Corporation
  • 7. DiaSorin S.p.A.
  • 8. Epitope Diagnostics Inc.
  • 9. F. Hoffmann-La Roche AG
  • 10. Fujirebio Diagnostics Inc.
  • 11. Guangzhou Wondfo Biotech Co., Ltd.
  • 12. Hologic Inc.
  • 13. Johnson & Johnson Services, Inc.
  • 14. Life Diagnostics, Inc.
  • 15. LSI Medience Corporation
  • 16. Meridian Bioscience, Inc.
  • 17. Myriad RBM Inc.
  • 18. PerkinElmer, Inc.
  • 19. Quest Diagnostics Incorporated
  • 20. Quidel Corporation
  • 21. QuidelOrtho Corporation
  • 22. Randox Laboratories Limited
  • 23. Sekisui Medical Co., Ltd.
  • 24. Siemens Healthineers AG
  • 25. Singulex, Inc.
  • 26. Sysmex Corporation
  • 27. Thermo Fisher Scientific Inc.
  • 28. Tosoh Corporation
  • 29. Trinity Biotech plc

LIST OF FIGURES

  • FIGURE 1. CARDIAC BIOMARKER MARKET MULTI-CURRENCY
  • FIGURE 2. CARDIAC BIOMARKER MARKET MULTI-LANGUAGE
  • FIGURE 3. CARDIAC BIOMARKER MARKET RESEARCH PROCESS
  • FIGURE 4. CARDIAC BIOMARKER MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CARDIAC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. CARDIAC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. CARDIAC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CARDIAC BIOMARKER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CARDIAC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CARDIAC BIOMARKER MARKET DYNAMICS
  • TABLE 7. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BNP & NT-PROBNP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CREATINE KINASE (CK) MB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. CARDIAC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 237. CARDIAC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2024